INmune Bio Inc. (INMB)

CIK 0001711754 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 —
Q1-2026 —
Latest FY-2025 —
Q3-2025 8-K (2025-10-30) · 99.1
Q2-2025 8-K (2025-08-07) · 99.1 · 99.2
Q1-2025 8-K (2025-05-08) · 99.1
FY-2024 8-K (2025-03-27) · 99.1  |  8-K (2024-11-01) · 99.1
Q3-2024 8-K (2024-08-02) · 99.1
Q2-2024 8-K (2024-05-13) · 99.1 · 99.2
Q1-2024 8-K (2024-03-29) · 99.1
FY-2023
FY-2023 —
Q3-2023 8-K (2023-11-01) · 99.1  |  8-K (2023-08-08) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Document and Entity Information
—
Audit Information
—
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (unaudited) (P)
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Changes In Stockholders Equity
Consolidated Statements of Operations and Comprehensive Loss (P)
Consolidated Statements of Cash Flows
Notes
Collaborative Agreements
Commitments
—
Commitments and Contingencies
—
Cybersecurity Risk Management and Strategy Disclosure
—
Debt
Equipment, Net
Fair Value Measurements
Going Concern
Government Grant
—
Income Taxes
—
Insider Trading Arrangements
Leases
Legal
—
Liquidity
—
Organization and Basis of Presentation
—
Organization and Description of Business
—
Organization and Significant Accounting Policies
—
Pay Vs Performance Disclosure
Related Party Transactions
Research and Development Activity
Segment Information
—
Stockholders Equity
Subsequent Events
Summary of Significant Accounting Policies